La Jolla, California
August 4, 2000
Akkadix
Corporation, an international agricultural gene discovery and
functional genomics company, announced today the signing of a
three-year agreement with the Missouri Soybean Merchandising Council
relating to the funding of research directed to the improvement of
soybean crops.
Under the agreement, Akkadix will manage research
programs that will be funded by the Missouri Soybean Merchandising
Council. The research will be carried out principally at the
University of Missouri. Intellectual property that is developed under
the sponsored research programs will be licensed to Akkadix for
further development and commercialization.
According to Jerry Caulder, CEO of Akkadix,
"The collaboration between the Missouri Soybean Merchandising
Council and Akkadix in this program will help leverage the strengths
of the two organizations, provide enhanced value to farmers and create
new soybean crop opportunities. We have chosen the University of
Missouri as the focal point for the research because it is a
recognized leader in this area." Under the agreement, Akkadix’s
responsibilities will be to identify target traits and technologies,
especially those that would be of benefit to Missouri farmers, and to
make all of the intellectual property developed under the research
programs first available to Missouri soybean farmers.
In May, Akkadix announced that it had acquired
exclusive rights to a gene discovery technology ("TraitFinder™")
that was developed jointly by Dr. Martin Yanofsky at the University of
California, San Diego and Dr. Detlef Weigel at The Salk Institute, and
that it had entered into exclusive consulting agreements with the
aforementioned scientists, and Dr. Julian Schroeder of the University
of California, San Diego, to advise Akkadix on utilizing this
technology for the identification of new plant traits. Dr. Joanne
Chory, a member of Akkadix’s Scientific Advisory Board will also
participate as an advisor to this unique program.
In March, Akkadix announced the extension and
expansion of its research relationship with the University of
Edinburgh for an additional period of three years. Research activities
under this relationship will comprise seven separately funded areas:
Plant growth control; Plant stature and organ size; Embryo, seed and
fruit development; Disease, pathogen and pest resistance; Plant
primary and secondary metabolism; and Natural product pathways.
Developments arising under these programs will be available to Akkadix
on an exclusive worldwide bass for all crops.
In February, Akkadix announced that it had licensed
certain gene technologies developed by Dr. Vicki B. Vance from the
South Carolina Research Institute. The licensed gene technologies are
useful to ensure durable, high-level expression of transgenes in crop
plants. In addition, Akkadix also announced that it had entered into a
three-year research Agreement to fund Dr. Vance’s on-going research
into an important viral defense phenomenon in plants known as
post-transcriptional gene silencing.
In January of this year, Akkadix also announced the
establishment of a research collaboration with The Philippine Rice
Institute (PhilRice) for gene discovery in rice. Developments arising
under this program will also be available to Akkadix on a worldwide
basis, and to PhilRice for use in the Philippines.
Equity funding for Akkadix Corporation has come
from venture capital investments by Bay City Capital Fund I, L.P,
North American Nutrition and Agribusiness Fund, L.P. (which is also
managed by Bay City Capital, LLC.), and the Missouri Soybean
Merchandising Council. Corporate shareholders include Axys
Pharmaceuticals, Inc. and Forage Genetics, Inc.
Akkadix Corporation is a global agricultural
biotechnology and foundation seed company that uses gene discovery,
functional genomics, bioinformatics, plant breeding and other
technologies for the discovery and delivery of novel plant traits
which improve health and safety, increase production, lower costs,
help preserve the environment and create new opportunities for
agriculture.